4 ms·
Its interesting that one of the drugs mentioned isnt viable as a business model because it must be given intravenously. Its almost like the value stream / value
by thinkingkong 6y ago
Its interesting that one of the drugs mentioned isnt viable as a business model because it must be given intravenously. Its almost like the value stream / value chain in medicine expects the drugs to do the work as a replacement for people. If the cost of an in-person visit was free, it would still cost more but might it be viable?
- sithadmin 6y agoIt's not just that there's friction associated with injection-only antibiotics. It's also that most cutting edge antibiotics that must be delivered via injection or infusion tend to be finicky about dose titration (requiring regular blood tests and hence effectively have secondary product dependencies to support use of the antibiotic), and have an unfortunate tendency to cause a number of relatively severe side effects that need to be monitored for over an extended duration.